Business Context and Reporting Period
This Form 10-Q covers The Procter & Gamble Company for the quarterly period ended December 31, 2003, and the six-month period ended December 31, 2003. The Company operates in five segments: Fabric & Home Care, Beauty Care, Baby & Family Care, Health Care, and Snacks & Beverages. A defining event for this period was the acquisition of a controlling interest (81%) in Wella AG in September 2003 for approximately $5.1 billion, which significantly impacted the Beauty Care segment and consolidated financial results.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2003 | Six Months Ended Dec 31, 2003 |
|---|---|---|
| Net Sales | $13,221 million | $25,416 million |
| Net Earnings | $1,818 million | $3,579 million |
| Diluted EPS | $1.30 | $2.56 |
| Operating Income | $2,742 million | $5,385 million |
| Operating Margin | 20.7% | 21.2% |
| Gross Margin | 52.2% | 52.0% |
| Cash from Operations | N/A | $3,961 million |
| Total Debt (Current + Long-Term) | $18,521 million | $18,521 million |
| Cash and Equivalents | $4,943 million | $4,943 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 20% for the quarter and 17% for the six-month period compared to the prior year. Growth was driven by a 19% increase in unit volume (9% organic) and a 4% positive foreign exchange impact, partially offset by pricing and mix.
- Earnings Growth: Net earnings rose 22% for the quarter and 21% for the six-month period. This was driven by volume benefits, lower manufacturing costs, and the completion of a restructuring program in the prior year.
- Margin Expansion: Gross margin expanded by 210 basis points (quarter) and 240 basis points (six months). Improvements were attributed to the higher-margin Wella acquisition, volume scale, and product cost savings.
- Acquisition Impact: The Wella acquisition contributed significantly to sales and earnings in the Beauty Care segment, which saw sales grow 50% and earnings grow 34% for the quarter.
- Working Capital: Accounts receivable increased by $1.4 billion (quarter-over-quarter) primarily due to strong December shipments. Inventory levels also rose significantly.
Guidance, Outlook, and Risks
- Outlook: Management expects double-digit top-line growth for the fiscal year in Health Care. Treasury share repurchases for the remainder of the fiscal year are expected to be higher than the prior year.
- Wella Integration: The Company is finalizing the purchase price allocation for Wella, which may result in adjustments to goodwill and intangible assets. Pro forma results indicate the acquisition was accretive to earnings.
- Regulatory Risks: The Medicare Prescription Drug Act of 2003 is not expected to have a material impact on postretirement benefit obligations due to federal subsidies. New accounting rules (FIN 46R) regarding variable interest entities are not expected to materially impact financial position.
- Market Risks: Results are subject to foreign exchange fluctuations, competitive pricing pressures, and commodity cost increases. Developing markets continue to show strong growth but carry inherent volatility.
Investor Verification Checklist
- Wella Valuation: Verify the final purchase price allocation for Wella AG, specifically the amount allocated to goodwill versus identifiable intangible assets, as preliminary estimates are subject to revision.
- Organic Growth: Confirm the 9% organic unit volume growth rate excluding acquisitions to assess underlying business momentum.
- Debt Structure: Review the increase in short-term debt ($5.885 billion) used to fund the Wella acquisition and the Company's ability to refinance at favorable rates.
- Margin Sustainability: Assess whether the gross margin expansion is sustainable given the offsetting impacts of pricing actions and rising commodity costs.
- Working Capital Trends: Monitor the significant increase in accounts receivable and inventory to ensure it aligns with sales growth and does not indicate collection or obsolescence issues.